

Rheumatoid Arthritis Drugs Market by Drug Class (Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, and Others), Route of Administration (Oral and Parenteral), and Sales Channel (Prescription-based Drugs, and Over-the-counter Drugs): Global Opportunity Analysis and Industry Forecast, 2027

<https://marketpublishers.com/r/R55DC49C873AEN.html>

Date: July 2023

Pages: 200

Price: US\$ 4,500.00 (Single User License)

ID: R55DC49C873AEN

Abstracts

The Rheumatoid Arthritis (RA) drugs market refers to the pharmaceuticals and biologic therapies developed for the treatment of rheumatoid arthritis, an autoimmune disease characterized by chronic inflammation of the joints. The goal of RA treatment is to manage symptoms, slow down the progression of the disease, and improve the quality of life for patients. The global healthcare expenditure has been steadily increasing, driven by factors such as population growth, aging demographics, and the prevalence of chronic diseases like RA. Governments and healthcare organizations are investing more in healthcare infrastructure and treatment options, including RA drugs. This increased healthcare spending contributes to the growth of the Rheumatoid Arthritis drugs market. The market is majorly restricted by the alternative treatment options. Rheumatoid Arthritis Drugs Market is likely to grow at a rate of 3.0% CAGR by 2027.

Rheumatoid Arthritis Drugs Market based on Drug Class Type

BS with Diarrhea (IBS-D)

IBS with Constipation (IBS-C)

Mixed-presentation IBS (IBS-M)

Rheumatoid Arthritis Drugs Market based on Route Of Administration

Rifaximin
Eluxadoline
Lubiprostone
Linaclotide

Rheumatoid Arthritis Drugs Market based on Sales Channel

Prescription-based Drugs
Over-the-counter Drugs

Rheumatoid Arthritis Drugs Market based on Geography

North America
Europe
Asia Pacific
Rest of the World

The market for rheumatoid arthritis drugs is driven by the increasing prevalence of the disease globally and the growing demand for effective treatment options. Various types of medications are used in the management of RA, including:

Nonsteroidal Anti-inflammatory Drugs (NSAIDs): NSAIDs are commonly used to relieve pain and reduce inflammation in RA. These drugs help alleviate symptoms but do not slow down the progression of the disease.

Disease-Modifying Antirheumatic Drugs (DMARDs): DMARDs are a class of medications that work to slow down the progression of RA by targeting the underlying autoimmune response. Conventional DMARDs, such as methotrexate, sulfasalazine, and leflunomide, are often prescribed as first-line treatments. They help reduce inflammation, relieve symptoms, and protect joint structures.

Biologic Response Modifiers: Biologic DMARDs, also known as biologics, are a newer class of drugs that target specific molecules in the immune system involved in the inflammatory response of RA. Biologics, such as tumor necrosis factor (TNF) inhibitors, interleukin (IL) inhibitors, and Janus kinase (JAK) inhibitors, have revolutionized the treatment of RA and have shown significant efficacy in reducing symptoms, preventing

joint damage, and improving long-term outcomes.

Corticosteroids: Corticosteroids are potent anti-inflammatory medications that can provide rapid relief of RA symptoms. They are often used for short-term management during disease flares or as a bridge therapy while waiting for other medications to take effect. Long-term use of corticosteroids is generally avoided due to their potential side effects.

The rheumatoid arthritis drugs market is highly competitive, with several pharmaceutical companies involved in research, development, and marketing of these medications. Advances in biotechnology and the emergence of biosimilars (lower-cost versions of biologic drugs) have increased treatment options and affordability.

The major leading companies of the rheumatoid arthritis drugs market are Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly And Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis Ag (Sandoz), Pfizer Inc., Ucb S.A.

In addition to pharmaceuticals, the market also includes healthcare providers, rheumatologists, and other healthcare professionals who diagnose and manage RA. Physical therapists and occupational therapists also play essential roles in improving patients' physical function and quality of life.

As research continues and our understanding of the underlying mechanisms of rheumatoid arthritis expands, new therapeutic targets and innovative drugs are expected to enter the market. Personalized medicine approaches, such as precision therapies based on genetic and biomarker profiles, may also shape the future of RA treatment.

It's worth observing that market trends and dynamics can change over time. For the most up-to-date information on the current state of the cephalosporin market, it is advisable to refer to recent market research reports, industry publications, and engage with experts in the pharmaceutical sector. An exclusive analysis of all key geographical regions is included in the report which determines the potential opportunities in these regions.

Detailed information about the attributes which are generating growth in the rheumatoid arthritis drugs market in the forecast period.

An exact estimation of the rheumatoid arthritis drugs market share and its contribution to the parent market is provided in the report.

Further profiles of major competitors and their dynamic strategies are also included in the report.

Contents

1. EXECUTIVE SUMMARY

2. INDUSTRY OUTLOOK

2.1. Industry Overview

2.2. Industry Trends

3. MARKET SNAPSHOT

3.1. Market Definition

3.2. Market Outlook

3.2.1. Porter Five Forces

3.3. Related Markets

4. MARKET CHARACTERISTICS

4.1. Market Overview

4.2. Market Segmentation

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. DRO - Impact Analysis

5. DRUG CLASS TYPE: MARKET SIZE & ANALYSIS

5.1. Disease-modifying Anti-rheumatic Drugs (DMARDs)

5.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

5.3. Corticosteroids

5.4. Uric Acid Drugs

6. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS

6.1. Oral

6.2. Parenteral

7. SALES CHANNEL: MARKET SIZE & ANALYSIS

7.1. Prescription-based Drugs

7.2. Over-the-counter Drugs

8. GEOGRAPHY: MARKET SIZE & ANALYSIS

8.1. Overview

8.2. North America

8.3. Europe

8.4. Asia Pacific

8.5. Rest of the World

9. COMPETITIVE LANDSCAPE

9.1. Competitor Comparison Analysis

9.2. Market Developments

9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships

9.2.2. Product Launches and execution

10. VENDOR PROFILES

10.1. ELI LILLY AND COMPANY.

10.1.1. Overview

10.1.2. Financial Overview

10.1.3. Product Offerings

10.1.4. Developments

10.1.5. Business Strategy

10.2. JOHNSON & JOHNSON

10.2.1. Overview

10.2.2. Financial Overview

10.2.3. Product Offerings

10.2.4. Developments

10.2.5. Business Strategy

10.3. F. HOFFMANN-LA ROCHE LTD

10.3.1. Overview

10.3.2. Financial Overview

10.3.3. Product Offerings

10.3.4. Developments

10.3.5. Business Strategy

10.4. NOVARTIS AG (SANDOZ).

- 10.4.1. Overview
- 10.4.2. Financial Overview
- 10.4.3. Product Offerings
- 10.4.4. Developments
- 10.4.5. Business Strategy

10.5. AMGEN INC

- 10.5.1. Overview
- 10.5.2. Financial Overview
- 10.5.3. Product Offerings
- 10.5.4. Developments
- 10.5.5. Business Strategy

10.6. UCB S.A.

- 10.6.1. Overview
- 10.6.2. Financial Overview
- 10.6.3. Product Offerings
- 10.6.4. Developments
- 10.6.5. Business Strategy

10.7. BRISTOL-MYERS SQUIBB COMPANY.

- 10.7.1. Overview
- 10.7.2. Financial Overview
- 10.7.3. Product Offerings
- 10.7.4. Developments
- 10.7.5. Business Strategy

10.8. PFIZER INC

- 10.8.1. Overview
- 10.8.2. Financial Overview
- 10.8.3. Product Offerings
- 10.8.4. Developments
- 10.8.5. Business Strategy

10.9. MERCK & CO., INC

- 10.9.1. Overview
- 10.9.2. Financial Overview
- 10.9.3. Product Offerings
- 10.9.4. Developments
- 10.9.5. Business Strategy

10.10. ABBVIE INC

- 10.10.1. Overview
- 10.10.2. Financial Overview

- 10.10.3. Product Offerings
- 10.10.4. Developments
- 10.10.5. Business Strategy

11. ANALYST OPINION

12. ANNEXURE

- 12.1. Report Scope
- 12.2. Market Definitions
- 12.3. Research Methodology
 - 12.3.1. Data Collation and In-house Estimation
 - 12.3.2. Market Triangulation
 - 12.3.3. Forecasting
- 12.4. Report Assumptions
- 12.5. Declarations
- 12.6. Stakeholders
- 12.7. Abbreviations

List Of Tables

LIST OF TABLES

TABLE 1. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)

TABLE 2. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDs), BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 3. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs), BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 4. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR CORTICOSTEROIDS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 5. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR URIC ACID DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 6. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 7. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 8. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR PARENTERAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 9. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)

TABLE 10. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR PRESCRIPTION-BASED DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 11. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR OVER-THE-COUNTER DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 12. NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 13. NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)

TABLE 14. NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 15. NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)

TABLE 16. U.S.RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)

TABLE 17. U.S.RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF

ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 18. U.S.RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)

TABLE 19. CANADARHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)

TABLE 20. CANADARHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 21. CANADARHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)

TABLE 22. EUROPERHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 23. EUROPERHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)

TABLE 24. EUROPERHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 25. EUROPERHEUMATOID ARTHRITIS DRUGS MARKETVALUE, SALES CHANNEL,2021-2027 (USD BILLION)

TABLE 26. GERMANY RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)

TABLE 27. GERMANY RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 28. GERMANY RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)

TABLE 29. U.K RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)

TABLE 30. U.K RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 31. U.K RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)

TABLE 32. FRANCE RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE2021-2027 (USD BILLION)

TABLE 33. FRANCE RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 34. FRANCE RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)

TABLE 35. ITALY RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)

TABLE 36. ITALY RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 37. ITALY RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)

TABLE 38. SPAIN RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)

TABLE 39. SPAIN RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 40. SPAIN RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)

TABLE 41. ROE RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)

TABLE 42. ROE RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 43. ROE RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)

TABLE 44. ASIA PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 45. ASIA PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)

TABLE 46. ASIA PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 47. ASIA PACIFIC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)

TABLE 48. CHINA RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)

TABLE 49. CHINA RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 50. CHINA RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)

TABLE 51. INDIA RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)

TABLE 52. INDIA RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 53. INDIA RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)

TABLE 54. JAPAN RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)

TABLE 55. JAPAN RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 56. JAPAN RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES

CHANNEL, 2021-2027 (USD BILLION)

TABLE 57. REST OF APAC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)

TABLE 58. REST OF APAC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 59. REST OF APAC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)

TABLE 60. REST OF WORLD RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)

TABLE 61. REST OF WORLD RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 62. REST OF WORLD RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)

TABLE 63. ELI LILLY AND COMPANY: FINANCIALS

TABLE 64. ELI LILLY AND COMPANY: PRODUCTS & SERVICES

TABLE 65. ELI LILLY AND COMPANY: RECENT DEVELOPMENTS

TABLE 66. JOHNSON & JOHNSON.: FINANCIALS

TABLE 67. JOHNSON & JOHNSON: PRODUCTS & SERVICES

TABLE 68. JOHNSON & JOHNSON: RECENT DEVELOPMENTS

TABLE 69. F. HOFFMANN-LA ROCHE LTD: FINANCIALS

TABLE 70. F. HOFFMANN-LA ROCHE LTD: PRODUCTS & SERVICES

TABLE 71. F. HOFFMANN-LA ROCHE LTD: RECENT DEVELOPMENTS

TABLE 72. NOVARTIS AG (SANDOZ): FINANCIALS

TABLE 73. NOVARTIS AG (SANDOZ): PRODUCTS & SERVICES

TABLE 74. NOVARTIS AG (SANDOZ): RECENT DEVELOPMENTS

TABLE 75. AMGEN INC: FINANCIALS

TABLE 76. AMGEN INC: PRODUCTS & SERVICES

TABLE 77. AMGEN INC: RECENT DEVELOPMENTS

TABLE 78. UCB S.A.: FINANCIALS

TABLE 79. UCB S.A: PRODUCTS & SERVICES

TABLE 80. UCB S.A: RECENT DEVELOPMENTS

TABLE 81. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS

TABLE 82. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES

TABLE 83. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS

TABLE 84. PFIZER INC: FINANCIALS

TABLE 85. PFIZER INC: PRODUCTS & SERVICES

TABLE 86. PFIZER INC: RECENT DEVELOPMENTS

TABLE 87. MERCK & CO., INC: FINANCIALS

TABLE 88. MERCK & CO., INC: PRODUCTS & SERVICES

TABLE 89. MERCK & CO., INC: RECENT DEVELOPMENTS

TABLE 90. ABBVIE INC: FINANCIALS

TABLE 91. ABBVIE INC: PRODUCTS & SERVICES

TABLE 92. ABBVIE INC: RECENT DEVELOPMENTS

I would like to order

Product name: Rheumatoid Arthritis Drugs Market by Drug Class (Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, and Others), Route of Administration (Oral and Parenteral), and Sales Channel (Prescription-based Drugs, and Over-the-counter Drugs): Global Opportunity Analysis and Industry Forecast, 2027

Product link: <https://marketpublishers.com/r/R55DC49C873AEN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R55DC49C873AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970